Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: Data from the AMSP study

European Archives of Psychiatry and Clinical Neuroscience

Volumn 264, Issue 2, 2014, Pages 131-141

  Grohmann, R ^a   Engel, R R ^a   Moller H J ^a   Ruther E ^a   Van Der Velden, J W ^b   Stubner S ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Adverse drug reactions; AMSP drug safety program; Antipsychotics; Drug use; Flupentixol

Indexed keywords

AMISULPRIDE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AKATHISIA; ARTICLE; BLOOD DYSCRASIA; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG UTILIZATION; DYSKINESIA; DYSLIPIDEMIA; DYSTONIA; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYNDROME; GALACTORRHEA; HEMATOLOGIC DISEASE; HUMAN; HYPERLIPIDEMIA; HYPOTENSION; LIVER DISEASE; MYOCARDITIS; NEUROLOGIC DISEASE; PARKINSONISM; PISA SYNDROME; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; TACHYCARDIA; TONIC CLONIC SEIZURE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; FEMALE; FLUPENTHIXOL; HUMANS; MALE; OBSERVATION; PRODUCT SURVEILLANCE, POSTMARKETING; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TIME FACTORS;

EID: 84896706385     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-013-0419-y     Document Type: Article

References (36)

1. Allison D, Mentore J, Heo M, Chandler L, Cappelleri J, Infante M, Weiden P (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696
2. Beamont P, Gleder M, Friesen H, Harris G, MacKinnon B, Mandelbrote B (1974) The effects of phenothiazines on endocrine function. Patients with inadequate lactation and amenorrhea. Br J Psychiatry 124:413-419
3. Canales PL, Olsen J, Miller AL et al (1999) Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs 12:179-188
4. Caroff SN, Mann SC, Campbell EC, Sullivan KA (2002) Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 63:12-19
5. Caroff SN (1980) The neuroleptic malignant syndrome. J Clin Psychiatry 41:79-83
6. Cicarelli E, Razzore P, Gaia D (2001) Hyperprolactinämia and provatine in benign intracranial tumors. J Neurosurg Sci 45:70
7. Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002) Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159:103-108
8. Engel RR, Grohmann R, Rüther E, Hippius H (2004) Research methods in drug surveillance. Pharmacopsychiatry 37(Suppl 1):12-15
9. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC (2004) Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 65:1377-1388
10. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167:686-693
11. Gattaz WF, Diehl A, Geuppert MS et al (2004) Olanzapine versus flupentixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial. Pharmacopsychiatry 37(Suppl 1):279-285
12. Glaser T, Sommermeyer H, Faßbender M, Mauler F (1998) Das Rezeptorbindungsprofil von cis-Flupentixol. In: Glaser T, Soyka M (eds) Flupentixol. Steinkopff Verlag, Darmstadt, pp 9-20
13. Grohmann R, Engel RR, Geissler KH, Rüther E (2004) Psychotropic drug use in psychiatric inpatients: recent trends and changes over time - data from the AMSP study. Pharmacopsychiatry 37(Suppl 1):27-38
14. Grohmann R, Engel RR, Rüther E, Hippius H (2004) The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37(Suppl 1):4-11
15. Grohmann R, Hippius H, Helmchen H, Rüther E, Schmidt LG (2004) The AMÜP study for drug surveillance in psychiatry - a summary of inpatient data. Pharmacopsychiatry 37(Suppl 1):16-26
16. Grohmann R, Rüther E (1994) Neuroleptika. In: Grohmann R, Rüther E, Schmidt LG (eds) Unerwünschte Wirkungen von Psychopharmaka. Springer, Berlin, pp 43-133
17. Gruber AJ, Cole JO (1991) Antidepressant effects of flupentixol. Pharmacotherapy 11:450-459
18. Gründer G, Hiemke C, Paulzen M, Veselinovic T, Vernaleken I (2011) Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. Pharmacopsychiatry 44:236-248
19. Hamner M, Arana G (1998) Hyperprolactinaemia in antipsychotic-treated patients: guidelines for avoidance and management. CNS Drugs 10:209-222
20. Hertling I, Philipp M, Dvorak A et al (2003) Flupentixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients. Neuropsychobiology 47:37-46
21. Hippius H, Kanig K (1958) Die Agranulocytose unter neuro-psychiatrischer Phenothiazin-Therapie. Ärztl Wochenschrift 13:501-507
22. Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva I (1977) Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 11:193-198
23. Leucht S, Corves C, Engel RR, Davies JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41
24. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123-136
25. Meisenzahl EM, Schmitt G, Gründer G, Dresel S, Frodl T, la Fougère C, Scheuerecker J, Schwarz M, Boerner R, Strauss J, Hahn K, Möller HJ (2008) Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry 41:169-175
26. Nasrallah H, Tandon R (2002) Efficacy, safety and tolerability of quetiapine in patients with schizophrenia. J Clin Psychiatry 63:12-20
27. Paton C, Lelliott P, Harrington M, Okocha C, Sensky T, Duffett R (2003) Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol 17(2):223-229
28. Ruhrmann S, Kissling W, Lesch OW et al (2007) Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Prog Neuropsychopharmacol Biol Psychiatry 31:1012-1022
29. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor bindings. Psychopharmacology 124:57-73
30. Stübner S, Rustenbeck E, Grohmann R, Wagner G, Engel R, Neundörfer G, Möller HJ, Hippius H, Rüther E (2004) Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 37(Suppl 1):54-64
31. Touraine P, Martini J, Zafrani B (1998) Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 83:667
32. Volavka J, Czobor P, Cooper T, Sheitman B, Lindenmayer P, Citrome L, McEvoy J, Lieberman J (2004) Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidon or haloperidol. J Clin Psychiatry 65:57-61
33. Vollset SE (1993) Confidence intervals for a binomial proportion. Stat Med 12:809-824
34. Wetterling T (2001) Bodyweight gain with atypical antipsychotics. Drug Saf 24:59-73
35. Wieck A, Haddad P (2002) Hyperprolactinemia caused by antipsychotic drugs. BMJ 324:250-252
36. Yood MU, DeLorenze G, Quesenberry CP Jr, Oliveria SA, Tsai AL, Willey VJ, McQuade R, Newcomer J, L'Italien G (2009) The incidence of diabetes in atypical antipsychotic users differs according to agent - results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 18(9):791-799